Immunitas Unveils Promising Phase 1/2a Trial Results for IMT-009 at AACR 2026 Annual Meeting#United_States#San_Diego#Immunitas_Therapeutics#IMT-009#AACR_2026
Immunitas Unveils Promising Phase 1/2a Trial Results for IMT-009 at AACR 2026 Annual Meeting
Immunitas Therapeutics showcased key Phase 1/2a data on IMT-009 at the AACR 2026 Annual Meeting, highlighting its potential in cancer treatment.
third-news.com
April 17, 2026 at 7:12 PM
Immunitas Unveils Promising Phase 1/2a Trial Results for IMT-009 at AACR 2026 Annual Meeting#United_States#San_Diego#Immunitas_Therapeutics#IMT-009#AACR_2026
Immunitas Therapeutics Unveils Breakthrough Data on IMT-380 for Autoimmunity at FASEB Conference#USA#Immunitas_Therapeutics#IMT-380#Anti-CD161#Niagara_Falls,_New_York
Immunitas Therapeutics Unveils Breakthrough Data on IMT-380 for Autoimmunity at FASEB Conference
Immunitas Therapeutics has unveiled preclinical findings on IMT-380, a pioneering anti-CD161 antibody, targeting autoimmune diseases at the FASEB Conference.
third-news.com
July 30, 2025 at 11:42 AM
Immunitas Therapeutics Unveils Breakthrough Data on IMT-380 for Autoimmunity at FASEB Conference#USA#Immunitas_Therapeutics#IMT-380#Anti-CD161#Niagara_Falls,_New_York